NCT04839575View on ClinicalTrials.gov

Study of Latiglutenase in T1D/CD Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
Celiac Disease
Interventions
DRUG

Latiglutenase

Administered orally (daily)

DRUG

Placebo

Administered orally (daily)

Trial Locations (1)

94306

Stanford University, Palo Alto

Sponsors

Collaborators (1)

Immunogenics, LLC
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Immunogenics, LLC

INDUSTRY

lead

Entero Therapeutics

INDUSTRY

NCT04839575 - Study of Latiglutenase in T1D/CD Patients | Biotech Hunter | Biotech Hunter